David R. Savello, Ph.D.
Dr. Savello joined XenoPort Inc. in 2005 and is presently Senior Vice President for development operations. Before XenoPort, Dr. Savello has held executive positions at Cardinal Health, Inc., Guilford Pharmaceuticals Inc., Glaxo and Glaxo Wellcome, Boehringer Ingelheim and 3M Riker Laboratories. While at Glaxo and Glaxo Wellcome, he was responsible for the development and regulatory submission and approval of a number of products including Serevent, Flovent, Flonase, Imitrex, Epivir, Zofran, and Zantac Rx to OTC switch.
He has been active throughout his professional career in scientific and trade associations. He was elected to the executive council for AAPS and served as Chairman for the Pharmaceutical Technology Section. He was a member of the Pharmaceutical Development Section of PhRMA for six years and served as Chairman of that committee. He was also a member and was elected chairman of the Regulatory Affairs Committee of PhRMA. Dr. Savello was a member of PhRMA’s FDA Modernization Act (FDAMA) Task Force working with Congressional leadership and FDA in developing legislation, which eventually was signed into law in 1996.
Dr. Savello also serves on a number of advisory boards. He served on the Board of Directors of Panacos Pharmaceuticals in Gaithersburg, MD. He presently serves on the Scientific Advisory Board of Pappas Ventures, a life sciences venture capital company in Research Triangle Park, NC. Dr. Savello is a Co-Founder and Principal for NDA Partners, LLC, a drug development consulting company.
Dr. Savello received his B.S. degree in pharmacy from the Massachusetts College of Pharmacy in Boston, M.A. and his M.S. and Ph.D. in pharmaceutics from the University of Maryland School of Pharmacy.